ClinicalTrials.gg
RecruitingNCT07563829Updated Sep 8, 2026

NPX372, a B7-H7:CD3 Bispecific Antibody, in Selected Solid Tumor Malignancies

A Phase 1 interventional study of NPX372 in Metastatic Malignant Neoplasm, sponsored by NextPoint Therapeutics, Inc.. Recruiting at 6 sites in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by NextPoint Therapeutics, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
81
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 2,057 studies in Neoplasm Metastasis with a site in United States — 345 open to participants now, 544 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
614th of 1,866
81 · median 43
Started
2026
with 85 others
Phase 1
710 of 2,057
127 open now
Primary completion
2027-04
later than 203 of 542 live
Registered
2,012th of 2,057
by date

Among the 2,057 studies in Neoplasm Metastasis with a site in United States, this one is the 614th largest by planned enrollment of the 1,866 interventional ones that give a count, is one of 86 that started in 2026, is one of 710 in phase 1, reaches primary completion later than 203 of the 542 other live ones, and was the 2,012th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

345 of the 2,057 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,057 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7.

In this research study we are:

  • Evaluating the safety and possible effectiveness of NPX372.
  • Identifying a safe and tolerable dose or doses for further study.

Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.

Read the detailed description

NPX372 is being developed as a therapeutic in solid tumor malignancies including non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), colorectal carcinoma (CRC), pancreatic adenocarcinoma (PDAC), biliary tract tumors, ovarian carcinoma, and gastric/gastro-esophageal carcinoma. This study is a Phase 1 study with primary dose-escalation occurring in the aforementioned solid tumor malignancies (main cohorts). Backfill cohorts from a selected subset of these tumor types will be utilized to enrich for dose optimization in participants whose tumors have high B7-H7 expression determined by prospective screening of archival tissue.

03

Conditions studied

  • Metastatic Malignant Neoplasm

Browse trials for

Keywords

  • solid tumor
  • B7-H7
  • bispecific antibody
  • dose escalation
  • CD3
  • HHLA2
  • T-cell engaging
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand and the willingness to sign a written document.
  • or cytologically confirmed recurrent or solid tumor to standard of care therapy in one of the following indications: NSCLC, RCC, CRC, PDAC, biliary tract tumors, gastric and gastro-esophageal carcinoma, and ovarian carcinoma.
  • by v1.1 criteria.
  • Age ≥19 years.
  • Adequate organ function as defined by:

    • Calculated (CrCl) must be ≥45 mL/min (by Cockroft-Gault formula).
    • Total ≤1.5× the (ULN) unless prior history of Gilbert's syndrome who must have total bilirubin \<3.0 mg/dL.
    • (AST) and alanine aminotransferase (ALT) ≤2.5× ULN, or ≤5× ULN if due to liver involvement by tumor.
    • Serum albumin ≥3.0 g/dL.
    • ≥9.0 g/dL, limited transfusion to reach this value may be allowed after discussion with the Sponsor's Medical Monitor.
    • ≥100 × 109 cells/L.
    • ≥1.5 ×109 cells/L.
    • Baseline oxygen saturation > 90% on room air
  • All participants will be required to have sufficient available. For backfill cohort participants, archival tissue will be used to confirm B7-H7 expression for enrollment (see inclusion criterion 2) during pre-screening.

    -If 3 participants are already enrolled in any backfill cohort, subsequent participants will be required to have a fresh biopsy during the screening period. These participants should therefore only be selected if judged safe to undergo a fresh biopsy.

  • Male participants with a female partner(s) of must agree to use highly effective measures throughout the trial starting with the Screening visit through 60 days after the last dose of study drug is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.

Exclusion criteria

EXCLUSION CRITERIA:

  • Prior treatment toxicity not resolved to grade 1 or below including any:

    • Systemic anti-cancer treatment: exceptions include alopecia, chronic stable neuropathy for >4 months, change in skin pigmentation, grade 2 anemia, or requiring replacement therapy for endocrine abnormalities (in this setting, symptoms should have resolved to grade 1 or below). Systemic anti-cancer treatment within 10 days prior to start of study is not allowed.
    • Limited-field radiotherapy: radiation therapy within 7 days prior to start of study or extended-field thoracic radiotherapy within 8 weeks of the first dose of study drug is not allowed.
    • Major surgery: major surgery (excluding placement of catheters, vascular access, or ) within 4 weeks of the first dose of study drug is not allowed.
  • Clinically or radiographically unstable : Participants with known brain metastases should be clinically stable and asymptomatic. Participants with a history of brain metastases should have an MRI during screening. For participants who are noted to have new or enlarging brain metastases during screening, treatment with stereotactic radiosurgery (SRS) is permitted with the standard limited field radiotherapy washout of >7 days. Participants requiring more extensive radiation (ie, fractionated stereotactic radiation or whole-brain radiation) would need a of ≥4 weeks. Participants should be off for central nervous system (CNS) treatment for at least 7 days prior to dosing.
  • Cardiac conditions as follows: history of congestive heart failure (CHF) Class III/IV according to the (NYHA) Functional Classification; cardiac arrhythmias >Grade 2, unstable angina, coronary/peripheral artery bypass graft within 3 months, or evidence of 2nd- or 3rd-degree heart block.
  • Uncontrolled intercurrent illness including, but not limited to, uncompensated respiratory, cardiac, hepatic, or renal disease, active infection (including virus [HBV], virus [HCV], [HIV] infections except as below, and active clinical tuberculosis), or renal transplant; ongoing or active infection, or social situations that would limit compliance with study requirements.

    • HIV: Seropositive participants without an acquired immunodeficiency syndrome (AIDS) defining illness and those with AIDS defining conditions on anti-retroviral therapy (ART) are eligible if they are healthy and have a >350 cells/mm3 at the time of screening (Day ≤28 days). Participants on ART must have HIV RNA levels \<50 copies/mL or the lower limit of quantification (LLOQ) using a local assay at the time of screening. Participants on ART must have been on a stable regimen without dose modification for at least 4 weeks prior screening.
    • HBV: Participants with HBsAg positivity are eligible if they have undetectable viral load and have received HBV anti-viral therapy for at least 4 weeks prior to screening.
    • HCV: Participants with a history of HCV infection are eligible if they have undetectable HCV viralload at screening and have completed curative therapy >4 weeks prior to screening.
  • Any evidence of hemoptysis or gastrointestinal (GI) bleeding within the last 3 months prior to screening.
  • Known disease requiring treatment requiring the equivalent of more than 10 mg prednisone daily.
  • History of unresolved prior immune-related toxicity except for endocrine abnormalities requiring replacement therapy or vitiligo.
  • Prior treatment with a cytokine therapy or cytokine fusion therapy.
  • History of prior or concomitant that requires other active treatment except for prostate cancer without radiographic evidence of disease on long-term androgen deprivation therapy for >6 months (ie, leuprolide).
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
81 participants (estimated)

Study arms

  • Experimental
    NPX372

    NPX372 is provided in single-use 5 mg vials at 1 mg per mL and is administered as an IV infusion over 60 minutes.

    Drug: NPX372

Interventions

  • DrugNPX372

    NPX372 is administered by IV infusion. The first cycle will be 3 weeks long and NPX372 will be given on the first day and one week later during this 3-week period. For most dose levels, the first day's dose (C1D1) will be a lower dose, which will serve as a "priming dose". The full dose will start on the second dose. After the first two doses, NPX372 will be administered every other week for up to 6 months. After that time, NPX372 will be given about once a month. Treatment may continue for up to 2 years as long as the patient is deriving benefit.

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicity (DLT)

    Number of participants with DLT

    Time frame: From first dose through 21 days

  2. Overall incidence of Dose Limiting Equivalent Toxicity (DLET) during treatment

    Number of participants with DLET

    Time frame: From first dose up to 24 months

  3. Incidence of AEs, characterized overall and by type, seriousness, relationship to NPX372, and severity.

    Number and type of AEs categorized by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: From first dose up to 24 months

  4. Number of participants with abnormal laboratory parameters, vital signs, electrocardiogram (ECG) parameters, physical examination findings as characterized by type, frequency, timing, relationship to NPX372, and severity

    Time frame: From first dose up to 24 months

  5. Drug discontinuation, drug interruptions/delays and dose reductions due to treatment-related AEs

    Number of participants with changes to their dosing schedule as a result of treatment-related AEs

    Time frame: From first dose up to 24 months

  6. Number of participants with AEs, DLTs (inclusive of DLETs), and PD changes within blood

    Time frame: From first dose up to 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)

    ORR: the proportion of participants with best overall response, i.e., complete response (CR) or partial response (PR), per RECIST 1.1

    Time frame: Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first

  2. Duration of Response (DOR)

    DOR: the time interval from first occurrence of a documented objective response to the time of disease progression as determined by the Investigator using RECIST 1.1 or death from any cause, whichever comes first.

    Time frame: Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first

  3. Disease Control Rate (DCR)

    DCR: the proportion of participants with a best ORR + Stable Disease (SD)

    Time frame: Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first]

  4. Progression-Free Survival (PFS)

    PFS: the duration from the start of treatment until tumor progression or death of any cause

    Time frame: Up to 2 years or until progressive disease, death, unacceptable toxicity, participant withdraw consent or investigator's decision, whichever occurs first

  5. NPX372 serum PK (Cmax)

    Cmax - measurement of highest NPX372 plasma concentration over time

    Time frame: Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)

  6. NPX372 serum PK (AUC0-last)

    AUC-last: measurement of total NPX372 plasma concentration over time

    Time frame: Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)

  7. NPX372 serum PK time of Cmax (Tmax)

    Tmax - time to NPX372 maxiumum plasma concentration

    Time frame: Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)

  8. NPX372 serum PK terminal half-life (T1/2)

    T1/2 - measurement of the clearance of NPX372 from plasma over time

    Time frame: Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)

  9. Degree of accumulation, incidence, and magnitude of ADA

    Number of participants with anti-drug antibodies (ADA)

    Time frame: Following dose on Day 1 for Cycle 1 (21 days). Following dose on Day 1 for Cycles 2 through 7 (28 days). Following dose on Day 1 every 3 cycles up to the end of treatment and 90-day follow-up after Cycle 7 (28 days)

  10. Overall Survival (OS)

    Average length of survival for treated participants

    Time frame: From first dose until death from any cause through 24 months

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2027, 11 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 11 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2026
First posted
May 4, 2026
StartActual
May 1, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07563829
Lead sponsor
NextPoint Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 1, 2026
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Trials nextpointtx
Contact
trials@nextpointtx.com
(508) 214-1115
Leena Gandhi, MD, Ph.D.
study director · NextPoint Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion